Advisory boards can generate some of the most valuable external scientific insights available to a Medical Affairs team, but only when the right experts are in the room, the right questions are being asked, and the discussion is structured to produce meaningful insight.

MedIntuit supports pharma and biotech companies across the scientific lifecycle of a scientific advisory board or medical advisory board, from defining objectives and identifying the right advisor profiles through agenda development, scientific content, facilitation, insight capture, and post-meeting synthesis.

Whether the goal is to explore an evolving treatment landscape, understand unmet needs, pressure-test a scientific strategy, prepare for a launch, or gather expert perspectives around a specific clinical question, we help ensure the pharma advisory board is designed around the decisions your Medical Affairs team actually needs to make.


Medical Affairs Competitive Intelligence

What This Service Includes

Advisory Board Strategy and Objective Setting

We work with your team to define the scientific and strategic questions the scientific advisory board needs to address, ensuring the meeting is built around clear objectives rather than a broad discussion without a defined outcome.

Advisor Identification, KOL Mapping, and Selection strategy

We help define the expertise, experience, geographic representation, practice setting, and stakeholder perspectives needed for the discussion. Support may include KOL mapping, advisor profiling, and development of selection criteria, with final advisor selection remaining with the client.

Agenda and Discussion Guide Development

We monitor publicly available clinical development activity, including trial initiations, study design changes, enrollment updates, data readouts, and key development milestones relevant to your competitive landscape.

Scientific Content Development and Review

We support the development or refinement of scientific background materials, pre-reads, presentations, discussion prompts, evidence summaries, and other materials needed to prepare advisors and facilitate an informed discussion.

Insight Capture and Synthesis

We organize advisory board feedback into clear scientific themes, areas of agreement and divergence, unanswered questions, evidence gaps, and potential implications for Medical Affairs

Who this is for

Pre-launch and commercial-stage pharma or biotech companies seeking external scientific perspectives around a product, pipeline, or treatment landscape

    • Medical Affairs teams planning a scientific advisory board or medical advisory board that need additional strategy, content, facilitation, or insight support

    • Emerging companies conducting their first pharmaceutical advisory board and looking for an experienced Medical Affairs partner to help establish the approach

    • Teams entering a new therapeutic area or indication that need structured input from external experts

    • Medical Affairs leaders seeking deeper, more actionable insights from an existing advisory board program

    • Organizations planning a KOL advisory board around a launch, evidence gap, treatment landscape, or other defined scientific question

Potential Deliverables

Depending on the engagement, support may include:

  • Competitive landscape analysis

  • Competitor pipeline tracker

  • Clinical development monitoring

  • Publication and evidence landscape review

  • Congress intelligence reports

  • Competitor data-readout summaries

  • Scientific intelligence briefs

  • Scientific landscape analysis

  • Recurring competitive intelligence briefs

  • Medical Affairs or executive leadership summaries

  • Competitive landscape dashboards or tracking frameworks

  • Strategic implications and priority questions

  • Ad hoc intelligence support around key milestones or competitor developments

  • Pharma competitive intelligence reports tailored to launch, pipeline, congress, or strategic planning needs

Meeting Facilitation and Scientific moderation

MedIntuit can provide experienced scientific facilitation for virtual or in-person advisory boards, including a KOL advisory board or other expert scientific forum, helping guide discussion, explore differing perspectives, probe important themes, and ensure all participants have an opportunity to contribute.

Post-Advisory Board recommendations

We help translate the discussion into actionable next steps, including questions for further investigation, stakeholder engagement priorities, evidence-generation considerations, scientific communication needs, or other Medical Affairs activities.

How it works

STEP 01

Define The Intelligence Questions:

We identify the competitors, programs, therapeutic areas, scientific developments, and strategic questions that matter most to your team.

STEP 02

Build the Intelligence Framework:

We establish the sources, monitoring cadence, reporting structure, and analytical framework needed to track relevant developments consistently.

STEP 03

Analyze and Translate:

We synthesize new information, identify meaningful patterns and changes, and translate findings into implications your Medical Affairs team can use. For senior stakeholders, reporting can be structured around the decisions, risks, opportunities, and questions requiring attention rather than the volume of information collected.

STEP 04

Refine over Time:

For ongoing engagements, the intelligence scope evolves as competitors, pipeline milestones, and organizational priorities change.

Frequently Asked Questions

  • Both options are available. MedIntuit can conduct a focused competitive landscape analysis around a specific strategic question or milestone, or establish an ongoing monitoring and reporting process for teams that need continuous visibility.

  • Yes. Engagements can be scoped around a defined therapeutic area, competitor set, pipeline, asset, launch milestone, medical congress, or specific strategic question.

  • Competitive intelligence in pharma can help Medical Affairs leaders understand how competitor pipelines, clinical evidence, scientific narratives, congress activity, and treatment landscapes are evolving. MedIntuit focuses on interpreting those developments in the context of your Medical Affairs priorities, rather than simply reporting what changed.

  • The source mix depends on the engagement and may include publicly available clinical trial information, scientific publications, congress abstracts and presentations, company disclosures, regulatory information, pipeline updates, and other legitimate scientific and industry sources.

  • Platforms can help surface information. MedIntuit adds Medical Affairs context and interpretation, helping teams determine which developments matter, what questions they raise, and how they may affect scientific strategy, stakeholder engagement, evidence planning, or future priorities.

  • Effective pharma competitive intelligence services should do more than provide monitoring updates. They should help leaders understand which scientific, clinical, and competitor developments are material, how the landscape is changing, and what those changes may mean for Medical Affairs strategy and execution. MedIntuit structures each engagement around the client's specific strategic questions and decision needs.

  • Yes. Depending on scope, findings can be synthesized for Medical Affairs leadership, CMOs, executive teams, Field Medical leaders, scientific communications teams, or other relevant cross-functional stakeholders. The level of detail and reporting format can be adapted to the decisions each audience needs to make.

Need clearer visibility into your competitive landscape?

 Contact MedIntuit Consulting to discuss the scientific, clinical, and competitor intelligence your Medical Affairs team needs to make better-informed decisions.

Related Services

Medical Congress Strategy


Learn more →

Fractional Medical Affairs Leadership


Learn more →

Medical Affairs Architecture

Back to services →

Back to all Services

Back to services →